Programmable polymer developer Tissium announced that it raised nearly $43 million in a Series B funding round to support expansion. The company’s funding round reached approximately $42.8 million (€38.8 million) and included new investors BNP Paribas Developpement, the European Investment Fund, M&L Investments and ValQuest Partners, along with returning investors Bpifrance, CM-CIC Innovation, CapDecisif Management, […]
High-capacity nanoparticle holds potential for targeted cancer therapies
Chemists from the Mass. Institute of Technology developed a nanoparticle that they can pack with 3 or more drugs to create custom combination therapies for cancer, according to a study published this week in the Journal of the American Chemical Society. The team also revealed that cisplatin, a powerful anti-cancer drug, doesn’t work using the […]
MassDevice.com +3 | Baxter's CEO reaps $14M, Sapien trial cut short on adverse events, Devices plus drugs pose great potential
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Devices plus drugs may mean an earlier payoff
Michael Cima
Companies combining valuable devices with known drugs may be able to land a high-value exit before ever hitting the market, MIT researcher Michael Cima told a group of medical device industry leaders today.
Speaking at the Cooley Medical Device Growth conference in Boston, Cima urged med-tech companies and investors to consider drug-device combinations, acknowledging a higher up-front risk with the potential for an earlier and larger reward.
